Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
NCT ID: NCT04340024
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2015-09-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers for Prediction of Tumor Response to Radiotherapy
NCT03744819
Tumor Response in Hypofractionated Radiotherapy
NCT02854449
Stereotactic Volumetric Radiotherapy in Prostate Cancer
NCT02423889
Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer
NCT02313298
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
NCT03035890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a type of cancer that is associated with sensitivity to radiotherapy
Exclusion Criteria
21 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Medical Research Council (NMRC), Singapore
OTHER_GOV
Duke-NUS Graduate Medical School
OTHER
Ferring Pharmaceuticals
INDUSTRY
ImmunoSCAPE
INDUSTRY
Decipher Biosciences
UNKNOWN
National Cancer Centre, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melvin Chua, MD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Centre, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center Singapore
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DISCLOSE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.